Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease.

P Sestini1, E Renzoni, S Robinson

  • 1Institute of Respiratory Diseases, University of Siena, Viale Bracci 3, 53100, Siena, Italy. sestini@unisi.it

The Cochrane Database of Systematic Reviews
|January 10, 2003
PubMed
Summary

Regular use of short-acting beta-2 agonists in stable Chronic Obstructive Pulmonary Disease (COPD) improves lung function and reduces breathlessness. Patients show a strong preference for these bronchodilators over placebo, with fewer dropouts, though long-term side effects require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma and allergies in schoolchildren: data from the European SINPHONIE study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic.

Pulmonology·2022
Same author

Effects of rituximab therapy on B cell differentiation and depletion.

Clinical rheumatology·2020
Same author

Omalizumab treatment in Samter's triad: case series and review of the literature.

European review for medical and pharmacological sciences·2019
Same author

NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Clinical and experimental medicine·2019
Same author

Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype?

Respiratory medicine case reports·2019

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive airflow limitation.
  • Short-acting beta-2 bronchodilators offer symptomatic improvement despite limited reversibility in COPD patients.
  • These medications are integral to managing both stable COPD and acute exacerbations.

Purpose of the Study:

  • To evaluate the clinical effectiveness of regular short-acting beta-2 agonist treatment in stable COPD patients.
  • To assess the adverse effects associated with this regular bronchodilator therapy.

Main Methods:

  • Conducted a systematic search of the Cochrane Airways Group database and relevant literature.
  • Included randomized controlled trials (RCTs) of at least one week comparing short-acting beta-2 agonists with placebo in stable COPD.

Related Experiment Videos

  • Employed independent data extraction and quality assessment, with author contact for missing information.

    • Main Results:

    • Thirteen high-quality crossover RCTs demonstrated significant improvements in FEV1, FVC, and PEFR compared to placebo.
    • Patients reported decreased breathlessness and preferred beta-2 agonists over placebo, with reduced treatment failure rates.
    • One study indicated significant improvements in dyspnea and fatigue scores; no serious side effects were reported, but study limitations precluded long-term safety assessment.

    Conclusions:

    • Regular short-acting beta-2 agonist use in stable COPD enhances lung function and alleviates breathlessness.
    • Patient preference and adherence are significantly higher with beta-2 agonists compared to placebo.
    • While beneficial, further large-scale, long-term studies are necessary to fully understand side effects and impact on disease progression. Newer long-acting bronchodilators may offer practical advantages, but current evidence supports the utility of these established, cost-effective agents.